Drug class
Leukotriene Modulators
Leukotriene modulators—also commonly referred to as leukotriene modifiers—are a class of oral medications that interfere with the production or actions of leukotrienes, which are potent lipid mediators of inflammation, bronchoconstriction, mucosal edema, and mucus secretion. Read more about Leukotriene Modulators
52 drugs in this class 32 manufacturers
Drugs in Leukotriene Modulators
MONTELUKAST SODIUM
MONTELUKAST SODIUM
MONTELUKAST SODIUM
MONTELUKAST SODIUM
MONTELUKAST SODIUM
MONTELUKAST SODIUM
SINGULAIR (montelukast sodium)
SINGULAIR (montelukast sodium)
Leukotriene modulators—also commonly referred to as leukotriene modifiers—are a class of oral medications that interfere with the production or actions of leukotrienes, which are potent lipid mediators of inflammation, bronchoconstriction, mucosal edema, and mucus secretion.
The class comprises cysteinyl leukotriene receptor antagonists, such as montelukast and zafirlukast, which selectively block CysLT1 receptors, and 5-lipoxygenase inhibitors, such as zileuton, which halt leukotriene synthesis.
Therapeutically, these agents serve as long-term maintenance controllers to prevent and manage chronic asthma, prevent exercise-induced bronchoconstriction, and treat allergic rhinitis.
-
nih.gov
Leukotriene modulators—also commonly referred to as leukotriene modifiers—are a class of oral medications that interfere with the production or actions of leukotrienes, which are potent lipid mediators of inflammation, bronchoconstriction, mucosal edema, and mucus secretion The class comprises cysteinyl leukotriene receptor antagonists, such as montelukast and zafirlukast, which selectively block CysLT1 receptors, and 5-lipoxygenase inhibitors, such as zileuton, which halt leukotriene synthesis
-
drugs.com
Leukotriene modulators—also commonly referred to as leukotriene modifiers—are a class of oral medications that interfere with the production or actions of leukotrienes, which are potent lipid mediators of inflammation, bronchoconstriction, mucosal edema, and mucus secretion The class comprises cysteinyl leukotriene receptor antagonists, such as montelukast and zafirlukast, which selectively block CysLT1 receptors, and 5-lipoxygenase inhibitors, such as zileuton, which halt leukotriene synthesis
-
aaaai.org
Therapeutically, these agents serve as long-term maintenance controllers to prevent and manage chronic asthma, prevent exercise-induced bronchoconstriction, and treat allergic rhinitis
-
clevelandclinic.org
Therapeutically, these agents serve as long-term maintenance controllers to prevent and manage chronic asthma, prevent exercise-induced bronchoconstriction, and treat allergic rhinitis
-
nih.gov
Therapeutically, these agents serve as long-term maintenance controllers to prevent and manage chronic asthma, prevent exercise-induced bronchoconstriction, and treat allergic rhinitis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.